Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Olaparib in Adults With Recurrent/Metastatic Ewing’s Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01583543).
- Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05286827).
- Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- OLAPCOIndependent statistical analysis of OLAParib COmbinations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02576444).
- OLEIndependent statistical analysis of Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OLE-IEDATIndependent statistical analysis of Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- OLE2Independent statistical analysis of An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10): Complete Statistical AnalysisIndependent statistical analysis of Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01294241).
- OLFUS-VIPESIndependent statistical analysis of Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- OLIFIndependent statistical analysis of OptiMesh® for Lumbar Interbody Fusion Trial (OLIF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00764491).
- oligo-metsIndependent statistical analysis of A Study of Definitive Therapy to Treat Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02716974).
- OLIGOPELVISIndependent statistical analysis of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OLIVERIndependent statistical analysis of Evaluation of Bispectral Index (BIS™) and Levels of Sedation With Common Inhalational Anesthetics in Healthy Volunteers (OLIVER): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Olmesartan Comparison to Losartan in Hypertensive Subjects: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan Comparison to Losartan in Hypertensive Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949884).
- Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLOLIndependent statistical analysis of Our Lifestyles Our Lives: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02965729).
- Olopatadine Eye Drops and Allergy Skin Testing: Complete Statistical AnalysisIndependent statistical analysis of Olopatadine Eye Drops and Allergy Skin Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00775658).
- Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction – DOSE Finding Study: Complete Statistical AnalysisIndependent statistical analysis of Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- OLTERMSIndependent statistical analysis of Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OLYMPIAIndependent statistical analysis of TearCare System to Treat Dry Eye Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03857919).
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- OLYMPUSIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study: Complete Statistical AnalysisIndependent statistical analysis of Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23): Complete Statistical AnalysisIndependent statistical analysis of Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02378480).
- Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13): Complete Statistical AnalysisIndependent statistical analysis of Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02531438).
- Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04779242).
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Omalizumab in the Treatment of Peanut Allergy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in the Treatment of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949078).
- Omarigliptin (MK-3102) Clinical Trial – Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): Complete Statistical AnalysisIndependent statistical analysis of Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015): primary endpoint results, effect estimate with confidence interval,…
- Omega Tots Long Term Follow-up: Complete Statistical AnalysisIndependent statistical analysis of Omega Tots Long Term Follow-up: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05191823).
- Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00511810).
- Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder: Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01694667).
- Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG): Complete Statistical AnalysisIndependent statistical analysis of Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OmegaREMODELIndependent statistical analysis of Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Omentectomy and Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Omentectomy and Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00923260).
- Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT: Complete Statistical AnalysisIndependent statistical analysis of Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OMS302-ILR-003Independent statistical analysis of Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OMWaNAIndependent statistical analysis of Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ON TARGET DMIndependent statistical analysis of Comparison of Type 2 Diabetes Pharmacotherapy Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073692).
- ON TRAXIndependent statistical analysis of Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- On-Eye Evaluation of Contact Lens Axis Location: Complete Statistical AnalysisIndependent statistical analysis of On-Eye Evaluation of Contact Lens Axis Location: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02100410).
- On-OffIndependent statistical analysis of On Versus Off Pump Myocardial Revascularization Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290952).
- ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management: Complete Statistical AnalysisIndependent statistical analysis of ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ONBOARDIndependent statistical analysis of Overcoming Barriers and Obstacles to Adopting Diabetes Devices (ONBOARD) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04672655).
- ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03295396).
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…